Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Tectonic Therapeutic ( (TECX) ) just unveiled an announcement.
On January 30, 2025, Tectonic Therapeutic announced positive interim results from its Phase 1b trial of TX45 in patients with Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF). The results, which achieved all hemodynamic goals, bolster the potential for TX45’s continued development into Phase 2 trials, potentially addressing unmet needs in a market with significant revenue potential.
More about Tectonic Therapeutic
Tectonic Therapeutic, Inc. is a clinical-stage biotechnology firm focused on the discovery and development of GPCR-target biologics for unmet medical needs. Founded in 2019 and public since June 2024, the company is advancing TX45 for pulmonary hypertension associated with heart failure and TX2100 for Hereditary Hemorrhagic Telangiectasia.
YTD Price Performance: -43.71%
Average Trading Volume: 143,803
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $360.6M
See more data about TECX stock on TipRanks’ Stock Analysis page.
